Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can cervical cancer patients stop immunotherapy early? new study investigates

NCT ID NCT07645625

Disease control Sponsor: University Medical Center Groningen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times

Summary

This study follows 261 people with persistent, recurrent, or metastatic cervical cancer who are taking pembrolizumab (Keytruda) with or without bevacizumab (Avastin). Some participants may choose to stop pembrolizumab early if their tumor shrinks or disappears, while others continue standard treatment. Researchers will track how long the cancer stays under control and compare results to previous trials, aiming to see if early discontinuation is a safe option.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pembrolizumab (Keytruda) with or without bevacizumab (Avastin)
What this could lead to
If successful, this could show that stopping pembrolizumab early is safe and effective for some patients with advanced cervical cancer, potentially reducing treatment burden.
What could go wrong
This is an observational registry, not a controlled trial, so results may be less definitive. Early discontinuation might lead to higher relapse risk, and findings may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 261 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Feb 2039

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria for the observation cohort: \- Persistent, recurrent, or metastatic cervical cancer commencing treatment or currently treated with a pembrolizumab containing regimen. Inclusion criteria for the early discontinuation cohort: * Previous inclusion in the observation cohort * Choice made to stop pembrolizumab for one of the following reasons: 1. Confirmed complete response if they had received at least 8 cycles of 3- weekly pembrolizumab, including at least 9 weeks beyond a CR (consistent with KEYNOTE-826 criteria) OR 2. Immune-related toxicity grade ≥ 3 OR 3. Patient's preference (e.g. chronic or invalidating grade 1-2 immune-related toxicity) OR 4. Confirmed partial response if they had received at least 8 cycles of 3- weekly pembrolizumab, including at least 9 weeks beyond a PR (timing consistent with KEYNOTE-826 criteria) * Eligible and willing to discontinue pembrolizumab (with or without discontinuing bevacizumab) Exclusion criteria for all cohorts are: * Malignant other disease other than cervical carcinoma that required active treatment in the past 2 years: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, transitional cell carcinoma of urothelial cancer, or any carcinoma in situ that have undergone potentially curative therapy are not excluded * Any psychological, familial, sociological or geographical condition or a known psychiatric or substance abuse disorder potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial. This comprises each and every condition or circumstance preventing the patient from showing up to the outpatient controls and/or undergoing the CT-scans, or preventing the patient from (adequately) filling out the questionnaires.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cervical cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Amsterdam UMC

    NOT_YET_RECRUITING

    Amsterdam, Netherlands

  • Antoni van Leeuwenhoek Ziekenhuis

    NOT_YET_RECRUITING

    Amsterdam, Netherlands

  • Catharina Ziekenhuis

    RECRUITING

    Eindhoven, Netherlands

  • Erasmus MC

    NOT_YET_RECRUITING

    Rotterdam, Netherlands

  • Isala Klinieken

    NOT_YET_RECRUITING

    Zwolle, Netherlands

  • LUMC

    RECRUITING

    Leiden, Netherlands

  • Maastricht UMC

    NOT_YET_RECRUITING

    Maastricht, Netherlands

  • Medisch Spectrum Twente

    NOT_YET_RECRUITING

    Enschede, Netherlands

  • Radboud UMC

    NOT_YET_RECRUITING

    Nijmegen, Netherlands

  • UMC Utrecht

    NOT_YET_RECRUITING

    Utrecht, Netherlands

  • University Mecdical Center Groningen

    RECRUITING

    Groningen, 9713 GZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.